Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19

Detalhes bibliográficos
Autor(a) principal: Picot, Stephane
Data de Publicação: 2020
Outros Autores: Marty, Aileen, Bienvenu, Anne-Lise, Blumberg, Lucille H., Dupouy-Camet, Jean, Carnevale, Pierre, Kano, Shigeyuki, Jones, Malcolm K., Daniel-Ribeiro, Cláudio Tadeu, MasComa, Santiago
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/40858
Resumo: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
id CRUZ_d029d5fc7f9de0e3181c10a4bb7a7ebf
oai_identifier_str oai:www.arca.fiocruz.br:icict/40858
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Picot, StephaneMarty, AileenBienvenu, Anne-LiseBlumberg, Lucille H.Dupouy-Camet, JeanCarnevale, PierreKano, ShigeyukiJones, Malcolm K.Daniel-Ribeiro, Cláudio TadeuMasComa, Santiago2020-04-19T01:34:27Z2020-04-19T01:34:27Z2020PICOT, Stephane et al. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, p. 1-16, Apr. 4, 2020.2352-7714https://www.arca.fiocruz.br/handle/icict/4085810.1016/j.onehlt.2020.100131Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.University Lyon. Malaria Research Unit. ICBMS. UMR 5246 CNRS INSA CPE. Lyon, France / Croix-Rousse Hospital. Hospices Civils de LyonInstitute of Parasitology and Medical Mycology. Lyon, France.Translational Medicine; HWCOM. FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development. Miami, Florida, USA.University Lyon. Malaria Research Unit. ICBMS. UMR 5246 CNRS INSA CPE. Lyon, France / Groupement Hospitalier Nord, Service Pharmacie. Hospices Civils de Lyon. Lyon, France.Deputy Director. Division of Public Health Surveillance and Response National Institute for Communicable Diseases. Johannesburg, South-Africa.Faculté de Médecine Paris Descartes. Académie Vétérinaire de France. Paris, France.Institute of Research for Development (former), Montpellier Centre. Montpellier France.National Center for Global Health and Medicine. Department of Tropical Medicine and Malaria, Research Institute. Tokyo, Japan.The University of Queensland. School of Veterinary Science. Brisbane, Qld, Australia.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa em Malária. Rio de Janeiro, RJ, Brazil.Universidad de Valencia. Facultad de Farmacia. Departamento de Parasitología. Valencia, Spain.Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.engElsevierhttps://www.arca.fiocruz.br/handle/icict/51608Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCOVID-19CoronavirusSARS-CoV-2HydroxychloroquineChloroquineSystemic lupus erythematosusImmunomodulationinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83134https://www.arca.fiocruz.br/bitstream/icict/40858/1/license.txt0ab46789d568c4ba27c7b5d29a9fe9c4MD51ORIGINALPicot_Stephane Picot_IOC_2020COVID19.pdfPicot_Stephane Picot_IOC_2020COVID19.pdfapplication/pdf595821https://www.arca.fiocruz.br/bitstream/icict/40858/2/Picot_Stephane%20Picot_IOC_2020COVID19.pdfe8b4e543dce4fea144da8063c42a328aMD52TEXTPicot_Stephane Picot_IOC_2020COVID19.pdf.txtPicot_Stephane Picot_IOC_2020COVID19.pdf.txtExtracted texttext/plain33903https://www.arca.fiocruz.br/bitstream/icict/40858/3/Picot_Stephane%20Picot_IOC_2020COVID19.pdf.txtfc6495a035d0c4c3e82ec8d3f965c249MD53icict/408582022-03-14 16:55:24.076oai:www.arca.fiocruz.br:icict/40858Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUw0KDQpDbGF1ZGV0ZSBGZXJuYW5kZXMsIENQRjogODgwLjg0OC44NDctMDAsIHZpbmN1bGFkbyBhIElDSUNUIC0gSW5zdGl0dXRvIGRlIENvbXVuaWNhw6fDo28gZSBJbmZvcm1hw6fDo28gQ2llbnTDrWZpY2EgZSBUZWNub2zDs2dpY2EgZW0gU2HDumRlCgpBbyBhY2VpdGFyIG9zIFRFUk1PUyBlIENPTkRJw4fDlUVTIGRlc3RhIENFU1PDg08sIG8gQVVUT1IgZS9vdSBUSVRVTEFSIGRlIGRpcmVpdG9zCmF1dG9yYWlzIHNvYnJlIGEgT0JSQSBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG86CgooMSkgQ0VERSBlIFRSQU5TRkVSRSwgdG90YWwgZSBncmF0dWl0YW1lbnRlLCDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVosIGVtCmNhcsOhdGVyIHBlcm1hbmVudGUsIGlycmV2b2fDoXZlbCBlIE7Dg08gRVhDTFVTSVZPLCB0b2RvcyBvcyBkaXJlaXRvcyBwYXRyaW1vbmlhaXMgTsODTwpDT01FUkNJQUlTIGRlIHV0aWxpemHDp8OjbyBkYSBPQlJBIGFydMOtc3RpY2EgZS9vdSBjaWVudMOtZmljYSBpbmRpY2FkYSBhY2ltYSwgaW5jbHVzaXZlIG9zIGRpcmVpdG9zCmRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIGR1cmFudGUgdG9kbyBvIHByYXpvIGRlIGR1cmHDp8OjbyBkb3MgZGlyZWl0b3MgYXV0b3JhaXMsIGVtCnF1YWxxdWVyIGlkaW9tYSBlIGVtIHRvZG9zIG9zIHBhw61zZXM7CgooMikgQUNFSVRBIHF1ZSBhIGNlc3PDo28gdG90YWwgbsOjbyBleGNsdXNpdmEsIHBlcm1hbmVudGUgZSBpcnJldm9nw6F2ZWwgZG9zIGRpcmVpdG9zIGF1dG9yYWlzCnBhdHJpbW9uaWFpcyBuw6NvIGNvbWVyY2lhaXMgZGUgdXRpbGl6YcOnw6NvIGRlIHF1ZSB0cmF0YSBlc3RlIGRvY3VtZW50byBpbmNsdWksIGV4ZW1wbGlmaWNhdGl2YW1lbnRlLApvcyBkaXJlaXRvcyBkZSBkaXNwb25pYmlsaXphw6fDo28gZSBjb211bmljYcOnw6NvIHDDumJsaWNhIGRhIE9CUkEsIGVtIHF1YWxxdWVyIG1laW8gb3UgdmXDrWN1bG8sCmluY2x1c2l2ZSBlbSBSZXBvc2l0w7NyaW9zIERpZ2l0YWlzLCBiZW0gY29tbyBvcyBkaXJlaXRvcyBkZSByZXByb2R1w6fDo28sIGV4aWJpw6fDo28sIGV4ZWN1w6fDo28sCmRlY2xhbWHDp8OjbywgcmVjaXRhw6fDo28sIGV4cG9zacOnw6NvLCBhcnF1aXZhbWVudG8sIGluY2x1c8OjbyBlbSBiYW5jbyBkZSBkYWRvcywgcHJlc2VydmHDp8OjbywgZGlmdXPDo28sCmRpc3RyaWJ1acOnw6NvLCBkaXZ1bGdhw6fDo28sIGVtcHLDqXN0aW1vLCB0cmFkdcOnw6NvLCBkdWJsYWdlbSwgbGVnZW5kYWdlbSwgaW5jbHVzw6NvIGVtIG5vdmFzIG9icmFzIG91CmNvbGV0w6JuZWFzLCByZXV0aWxpemHDp8OjbywgZWRpw6fDo28sIHByb2R1w6fDo28gZGUgbWF0ZXJpYWwgZGlkw6F0aWNvIGUgY3Vyc29zIG91IHF1YWxxdWVyIGZvcm1hIGRlCnV0aWxpemHDp8OjbyBuw6NvIGNvbWVyY2lhbDsKCigzKSBSRUNPTkhFQ0UgcXVlIGEgY2Vzc8OjbyBhcXVpIGVzcGVjaWZpY2FkYSBjb25jZWRlIMOgIEZJT0NSVVogLSBGVU5EQcOHw4NPIE9TV0FMRE8KQ1JVWiBvIGRpcmVpdG8gZGUgYXV0b3JpemFyIHF1YWxxdWVyIHBlc3NvYSDigJMgZsOtc2ljYSBvdSBqdXLDrWRpY2EsIHDDumJsaWNhIG91IHByaXZhZGEsIG5hY2lvbmFsIG91CmVzdHJhbmdlaXJhIOKAkyBhIGFjZXNzYXIgZSB1dGlsaXphciBhbXBsYW1lbnRlIGEgT0JSQSwgc2VtIGV4Y2x1c2l2aWRhZGUsIHBhcmEgcXVhaXNxdWVyCmZpbmFsaWRhZGVzIG7Do28gY29tZXJjaWFpczsKCig0KSBERUNMQVJBIHF1ZSBhIG9icmEgw6kgY3JpYcOnw6NvIG9yaWdpbmFsIGUgcXVlIMOpIG8gdGl0dWxhciBkb3MgZGlyZWl0b3MgYXF1aSBjZWRpZG9zIGUgYXV0b3JpemFkb3MsCnJlc3BvbnNhYmlsaXphbmRvLXNlIGludGVncmFsbWVudGUgcGVsbyBjb250ZcO6ZG8gZSBvdXRyb3MgZWxlbWVudG9zIHF1ZSBmYXplbSBwYXJ0ZSBkYSBPQlJBLAppbmNsdXNpdmUgb3MgZGlyZWl0b3MgZGUgdm96IGUgaW1hZ2VtIHZpbmN1bGFkb3Mgw6AgT0JSQSwgb2JyaWdhbmRvLXNlIGEgaW5kZW5pemFyIHRlcmNlaXJvcyBwb3IKZGFub3MsIGJlbSBjb21vIGluZGVuaXphciBlIHJlc3NhcmNpciBhIEZJT0NSVVogLSBGVU5EQcOHw4NPIE9TV0FMRE8gQ1JVWiBkZQpldmVudHVhaXMgZGVzcGVzYXMgcXVlIHZpZXJlbSBhIHN1cG9ydGFyLCBlbSByYXrDo28gZGUgcXVhbHF1ZXIgb2ZlbnNhIGEgZGlyZWl0b3MgYXV0b3JhaXMgb3UKZGlyZWl0b3MgZGUgdm96IG91IGltYWdlbSwgcHJpbmNpcGFsbWVudGUgbm8gcXVlIGRpeiByZXNwZWl0byBhIHBsw6FnaW8gZSB2aW9sYcOnw7VlcyBkZSBkaXJlaXRvczsKCig1KSBBRklSTUEgcXVlIGNvbmhlY2UgYSBQb2zDrXRpY2EgSW5zdGl0dWNpb25hbCBkZSBBY2Vzc28gQWJlcnRvIGRhIEZJT0NSVVogLSBGVU5EQcOHw4NPCk9TV0FMRE8gQ1JVWiBlIGFzIGRpcmV0cml6ZXMgcGFyYSBvIGZ1bmNpb25hbWVudG8gZG8gcmVwb3NpdMOzcmlvIGluc3RpdHVjaW9uYWwgQVJDQS4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogcmVzZXJ2YQpleGNsdXNpdmFtZW50ZSBhbyBBVVRPUiBvcyBkaXJlaXRvcyBtb3JhaXMgZSBvcyB1c29zIGNvbWVyY2lhaXMgc29icmUgYXMgb2JyYXMgZGUgc3VhIGF1dG9yaWEKZS9vdSB0aXR1bGFyaWRhZGUsIHNlbmRvIG9zIHRlcmNlaXJvcyB1c3XDoXJpb3MgcmVzcG9uc8OhdmVpcyBwZWxhIGF0cmlidWnDp8OjbyBkZSBhdXRvcmlhIGUgbWFudXRlbsOnw6NvCmRhIGludGVncmlkYWRlIGRhIE9CUkEgZW0gcXVhbHF1ZXIgdXRpbGl6YcOnw6NvLgoKQSBQb2zDrXRpY2EgSW5zdGl0dWNpb25hbCBkZSBBY2Vzc28gQWJlcnRvIGRhIEZJT0NSVVogLSBGVU5EQcOHw4NPIE9TV0FMRE8gQ1JVWgpyZXNwZWl0YSBvcyBjb250cmF0b3MgZSBhY29yZG9zIHByZWV4aXN0ZW50ZXMgZG9zIEF1dG9yZXMgY29tIHRlcmNlaXJvcywgY2FiZW5kbyBhb3MgQXV0b3JlcwppbmZvcm1hciDDoCBJbnN0aXR1acOnw6NvIGFzIGNvbmRpw6fDtWVzIGUgb3V0cmFzIHJlc3RyacOnw7VlcyBpbXBvc3RhcyBwb3IgZXN0ZXMgaW5zdHJ1bWVudG9zLgo=Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-03-14T19:55:24Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
title Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
spellingShingle Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
Picot, Stephane
COVID-19
Coronavirus
SARS-CoV-2
Hydroxychloroquine
Chloroquine
Systemic lupus erythematosus
Immunomodulation
title_short Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
title_full Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
title_fullStr Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
title_full_unstemmed Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
title_sort Coalition: Advocacy for Prospective Clinical Trials to Test the Post-Exposure Potential of Hydroxychloroquine Against COVID-19
author Picot, Stephane
author_facet Picot, Stephane
Marty, Aileen
Bienvenu, Anne-Lise
Blumberg, Lucille H.
Dupouy-Camet, Jean
Carnevale, Pierre
Kano, Shigeyuki
Jones, Malcolm K.
Daniel-Ribeiro, Cláudio Tadeu
MasComa, Santiago
author_role author
author2 Marty, Aileen
Bienvenu, Anne-Lise
Blumberg, Lucille H.
Dupouy-Camet, Jean
Carnevale, Pierre
Kano, Shigeyuki
Jones, Malcolm K.
Daniel-Ribeiro, Cláudio Tadeu
MasComa, Santiago
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Picot, Stephane
Marty, Aileen
Bienvenu, Anne-Lise
Blumberg, Lucille H.
Dupouy-Camet, Jean
Carnevale, Pierre
Kano, Shigeyuki
Jones, Malcolm K.
Daniel-Ribeiro, Cláudio Tadeu
MasComa, Santiago
dc.subject.en.pt_BR.fl_str_mv COVID-19
Coronavirus
SARS-CoV-2
Hydroxychloroquine
Chloroquine
Systemic lupus erythematosus
Immunomodulation
topic COVID-19
Coronavirus
SARS-CoV-2
Hydroxychloroquine
Chloroquine
Systemic lupus erythematosus
Immunomodulation
description Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
publishDate 2020
dc.date.accessioned.fl_str_mv 2020-04-19T01:34:27Z
dc.date.available.fl_str_mv 2020-04-19T01:34:27Z
dc.date.issued.fl_str_mv 2020
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv PICOT, Stephane et al. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, p. 1-16, Apr. 4, 2020.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/40858
dc.identifier.issn.pt_BR.fl_str_mv 2352-7714
dc.identifier.doi.pt_BR.fl_str_mv 10.1016/j.onehlt.2020.100131
identifier_str_mv PICOT, Stephane et al. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, p. 1-16, Apr. 4, 2020.
2352-7714
10.1016/j.onehlt.2020.100131
url https://www.arca.fiocruz.br/handle/icict/40858
dc.language.iso.fl_str_mv eng
language eng
dc.relation.hasversion.pt_BR.fl_str_mv https://www.arca.fiocruz.br/handle/icict/51608
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/40858/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/40858/2/Picot_Stephane%20Picot_IOC_2020COVID19.pdf
https://www.arca.fiocruz.br/bitstream/icict/40858/3/Picot_Stephane%20Picot_IOC_2020COVID19.pdf.txt
bitstream.checksum.fl_str_mv 0ab46789d568c4ba27c7b5d29a9fe9c4
e8b4e543dce4fea144da8063c42a328a
fc6495a035d0c4c3e82ec8d3f965c249
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798325035055710208

Registros relacionados